Gilead Sciences

Forecast & Rating28 analysts currently cover Gilead Sciences, with about 75.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $158.15, about 8.1% upside from the current price of $146.30. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 82.9% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Gilead Sciences closely still see room for the stock to rise. Data as of Sep 14, 2026; for reference only and not investment advice.